Synapse - Find an Expert

115370 Results

Total neoadjuvant FLOT chemotherapy in oesophagogastric adenocarcinoma: An international cohort study

Meeting Abstract

Clements, H. A.; Dobrzhanskiy, O.; Yang, J.; Bausys, A.; Ferri, L. E.; Ku, G. Y.; Smyth, E. C.; Underwood, T. J.; Petty, R. D.
Annals of Oncology (2024)

Fulltext@MSK | Save

First-line (1L) zolbetuximab + chemotherapy in patients (pts) with claudin 18.2 (CLDN18.2) +, HER2-, locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma: A pooled final analysis of SPOTLIGHT + GLOW

Meeting Abstract

Kang, Y. K.; Shah, M. A.; Shitara, K.; Ajani, J. A.; Lordick, F.; Van Cutsem, E.; Ilson, D. H.; Klempner, S. J.; Yamaguchi, K.; Nakajima, T.; more...
Annals of Oncology (2024)

Fulltext@MSK | Save

Trastuzumab deruxtecan (T-DXd) monotherapy and combinations in patients (pts) with advanced/metastatic HER2-positive (HER2+) esophageal, gastric or gastroesophageal junction adenocarcinoma (GEJA): DESTINY-Gastric03 (DG-03)

Meeting Abstract

Janjigian, Y. Y.; van Laarhoven, H. W. M.; Rha, S. Y.; Kozlov, V.; Oh, D. Y.; Gravina, A.; Rapatoni, L.; Shoji, H.; Hofheinz, R. D.; Chen, L. T.; more...
Annals of Oncology (2024)

Fulltext@MSK | Save

Phase III study of pembrolizumab plus MK-1084 vs pembrolizumab plus placebo as first-line treatment for metastatic non-small cell lung cancer (NSCLC) with a KRAS G12C mutation and PD-L1 tumour proportion score (TPS) ≥50%: MK-1084-004

Meeting Abstract

Cobb, P. W.; Hochmair, M.; Schuler, M. H. H.; Riely, G. J.; Rojas, C. I.; Kim, S. J.; Chen, X.; Lara-Guerra, H.; Felip, E.
Annals of Oncology (2024)

Fulltext@MSK | Save

Zanidatamab + chemotherapy for first-line (1L) treatment of HER2+ advanced or metastatic gastro-oesophageal adenocarcinoma (mGEA): New and updated data from a phase II trial

Meeting Abstract

Elimova, E.; Ajani, J. A.; Burris, H. A.; Denlinger, C. S.; Iqbal, S.; Kang, Y. K.; Kim, J. H.; Lee, K. W.; Lin, B.; Mehta, R.; more...
Annals of Oncology (2024)

Fulltext@MSK | Save

Final overall survival for the phase III, KEYNOTE-811 study of pembrolizumab plus trastuzumab and chemotherapy for HER2+ advanced, unresectable or metastatic G/GEJ adenocarcinoma

Meeting Abstract

Janjigian, Y. Y.; Kawazoe, A.; Bai, Y.; Xu, J.; Lonardi, S.; Metges, J. P.; Yanez Weber, P. E.; Wyrwicz, L. S.; Shen, L.; Ostapenko, Y. V.; more...
Annals of Oncology (2024)

Fulltext@MSK | Save

TRIDENT: Machine learning (ML) multimodal signatures to identify patients that would benefit most from tremelimumab (T) addition to durvalumab (D) + chemotherapy (CT) with data from the POSEIDON trial

Meeting Abstract

Skoulidis, F.; Jabbour, S.; Garon, E. B.; Iyengar, P.; Scagliotti, G.; Ferrer, L.; Etchepare, G.; Gallinato, O.; Faure, J.; Bernard, P.; more...
Annals of Oncology (2024)

Fulltext@MSK | Save

Sotorasib long-term clinical outcomes in pretreated KRAS G12C-mutated advanced NSCLC: Pooled analysis from the CodeBreaK clinical trials

Meeting Abstract

Skoulidis, F.; Li, B. T.; Hochmair, M. J.; Govindan, R.; Vincent, M.; Van Der Wekken, A. J.; Reguart Aransay, N.; O'Byrne, K. J.; Girard, N.; Griesinger, F.; more...
Annals of Oncology (2024)

Fulltext@MSK | Save

A population-level prognostic score model for early acquired resistance to frontline anti-PD-(L)1 therapy in metastatic non-small cell lung cancer (NSCLC)